Lantheus doses first patient in SPARROW Phase 2/3 prostate cancer imaging trial for LNTH-2401

By Public Technologies
  • Lantheus dosed the first patient in SPARROW, a Phase 2/3 registrational study of LNTH-2401 PET imaging in prostate cancer.
  • No clinical results were presented; the trial is designed to generate data for a future diagnostic performance readout.
  • The study aims to show LNTH-2401 can help detect and characterize prostate cancer using a GRPR-targeted approach complementary to PSMA imaging.
  • Phase 3 is expected to enroll about 400 participants, positioning the program as a potential pipeline expansion in prostate cancer imaging.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantheus Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280800PRIMZONEFULLFEED9834386) on September 28, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk